Esophageal Neoplasm Clinical Trials in Beijing, Beijing Municipality
4 recruitingBeijing, Beijing Municipality, China
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 3
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Esophageal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences436 enrolled1 locationNCT06086457
Recruiting
Phase 2
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Esophageal Neoplasm MetastaticEsophageal Cancer Stage IVb
Cancer Institute and Hospital, Chinese Academy of Medical Sciences120 enrolled1 locationNCT06084897